Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0004352 (
autism
)
32,579
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Introduction:
Microdeletions in the chromosomal region 2q34 and its neighboring regions lead to a phenotypic spectrum including
autism
, intellectual disability, and epilepsy. Up to now, only few affected patients have been reported. Therefore, the genetic pathogenesis is not completely understood. One of the most discussed candidate genes in this context is
MAP2
, a gene responsible for microtubule polymerization and neurite outgrowth.
Materials and Methods:
We present a 4.5-year-old male patient with epilepsy, mild developmental delay, and behavioral abnormalities. SNP-Array analysis was performed to search for pathogenic copy number variations.
Results:
SNP-Array analysis revealed a 1.5 Mb
de novo
microdeletion on the long arm of chromosome 2 (2q34). The identified microdeletion included the candidate genes
UNC80
, LANCL1
, and most importantly
MAP2
.
Discussion:
The reported microdeletion identified in this patient is the smallest one described in the literature so far spanning
MAP2
next to
UNC80
and
LANCL1
. In this context
MAP2
is the most important candidate gene concerning neuronal development and its function should be further examined.
...
PMID:
MAP2
- A Candidate Gene for Epilepsy, Developmental Delay and Behavioral Abnormalities in a Patient With Microdeletion 2q34. 2963 46